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scale, other (alpha  0.45); total score alpha levels were
excellent (0.95). Item correlations by subscale were in the
predicted direction; all were significant (r  0.29 to 0.77;
P  .001). Correlations between PAGI-SYM total and
subscale scores and SF-36 PCS and MCS scores were in
the predicted direction; all were significant (r  0.28 to
0.64; P  .0001). CONCLUSIONS: Results suggest the
PAGI-SYM is internally consistent with evidence of con-
tent and construct validity. Further research on the in-
strument’s reproducibility, sensitivity to change and the
definition of clinically-meaningful change in GERD and
dyspepsia symptoms is needed before use in clinical studies.
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OBJECTIVE: To calculate the break-even point as the
number of years after Laparoscopic Nissen fundoplica-
tion surgery where the surgery’s costs are equivalent to
the costs associated with omeprazole maintenance ther-
apy for patients with severe gastroesophageal reflux dis-
ease (GERD). METHODS: A Markov decision analytic
model was developed to estimate the direct medical costs
of each alternative for treating patients with severe GERD.
The payer perspective was utilized and a literature review
was conducted to identify the direct costs associated with
each approach. The probabilities used in the model were
estimated from published clinical trials. The Markov
model cycle was set equal to one year and the break-even
point was identified as the year in which the expected
values of the costs of each treatment were equal. Sensitiv-
ity analyses were performed. RESULTS: The break-even
point of the two therapies is approximately 12 years. By
subtracting 12 years from the average US life expectancy,
the break-even age is 64 years in which the costs of surgi-
cal treatment for persons under the age of 64 is less than
omeprazole for the remaining years of life. The results of
the sensitivity analyses will be reported. DISCUSSION:
This study provides evidence that Laparoscopic Nissen
fundoplication becomes a cost saving approach relative
to omeprazole therapy when omeprazole therapy is ex-
pected to last more than 12 years. This model assumes
omeprazole therapy is taken continuously over a pa-
tient’s lifetime to treat severe GERD and assumes that
successful surgery does not require maintenance omepra-
zole and lasts a patient’s lifetime. This procedure is a rel-
atively new technique and there is no long-term data on
the success rate. The standard prognosis of success for
the surgery used by gastroenterologists has been 10 years.
The surgical procedure may not be cost saving if the suc-
cess rate declines after 10 years. 
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OBJECTIVE: In the new Dutch General-Practitioner’s
guidelines, Helicobacter pylori (Hp) eradication is indi-
cated for patients with peptic ulcer disease (ulcus duodeni
and ulcus ventriculli). Pharmacotherapy for Hp-eradica-
tion comprises a combination of an antibiotic and a pro-
ton-pump inhibitor (PPI) or a bismuth preparation. Our
objective is to estimate gastrointestinal drug utilization
and related costs prior and post Hp-eradication. METH-
ODS: For the analysis we used a regional pharmacists’
database in the North of the Netherlands (“Interaction
Database”; total population: 130,000; period covered:
1994–98). We selected all patients with two prescriptions
on one day from the same doctor: one prescription for
antibiotics and one for PPI. In total 1210 potential eradi-
cations were found. Over 95% of the patients received at
least one of the following combinations: (i) PPI and amox-
icillin; (ii) PPI, clarithromycin and metronidazole; (iii)
PPI, clarithromycin and amoxicillin. RESULTS: Prelimi-
nary results indicate that in the four months prior to
eradication, 30% of the patients were on ranitidine main-
tenance therapy and 25% used PPIs, but 45% used nei-
ther. Costs of PPIs amount to approximately €500 per
patient in the year prior to eradication. Post-Hp-eradica-
tion results indicate that in the year after eradication,
costs per patient for PPIs decrease to approximately
€250. Updated results, comprising data for 1999 as well,
will be presented at the conference. CONCLUSIONS:
Preliminary results suggest that a significant share of Hp-
eradications occur in patients not using PPIs or raniti-
dine. Furthermore, on the short-term, costs per patient per
year for PPIs are reduced by 50% through Hp-eradication.
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